QIDP Drug Update – Part 2:  Categories of Interest

According to Janet Woodcock, 63 drugs have been given the “QIDP” designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development.  So we are in fairly close agreement. That Continue reading QIDP Drug Update – Part 2:  Categories of Interest

QIDP Antibiotics – 2015 Year-End Update

Here an updated listing of all QIDP drugs we are aware of as of 12/24/2015. Today just facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are 58 drugs which garnered QIDP status and these Continue reading QIDP Antibiotics – 2015 Year-End Update

QIDP Drugs: Here They Are, All of Them

For the latest QIDP listing, please click HERE As of Oct. 9, 2014, there were by my accounting 30 compounds with QIDP designation. Here is the break-down:   31 compounds with QIDP designation 29 antibacterials, 2  antifungals 22 systemically active, Continue reading QIDP Drugs: Here They Are, All of Them

The Difficult Transition Into Phase 3

Preclinical and early clinical development is expensive enough already for VC companies but it gets really expensive in Phase 3.  Hence, not surprisingly, few small companies tackle Phase 3 programs on their own.  Unless an ‘angel investor’ with deep pockets Continue reading The Difficult Transition Into Phase 3

Pleuromutilins Are Important to Control Brachyspira hyodysenteriae

Spirochetal colitis or swine dysentery is a disease of piglets with worldwide distribution.  It can cause severe bloody diarrheal disease with a mortality of up to 50% in herds if untreated and thus can have great economic impact.  The disease Continue reading Pleuromutilins Are Important to Control Brachyspira hyodysenteriae